745 results on '"Doebele, Robert C."'
Search Results
52. Supplementary Figures 1 - 5 from An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
53. Supplementary Figure 2 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
54. Supplementary Figure 1 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
55. Supplementary Figure 4 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
56. Figure S4 from ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms
57. Supplementary Data from Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
58. Supplementary Methods and Figure Legends from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
59. Supplementary Table 1 from ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms
60. Data from Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling
61. Data from ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms
62. Data from An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
63. Supplementary Figure 3 from Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
64. Supplementary Data from A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
65. Supplementary Figures and Tables from Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling
66. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
67. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer
68. Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
69. Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status
70. Supplementary Figures 1,2, 3 from Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
71. Supplementary Figures 1-5 from Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer
72. Supplementary Figure 2 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
73. Supplementary Figures 1-5, Tables 1-2 from Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
74. Data from Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins
75. Supplementary Figures S1-S10. from Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins
76. Supplementary Figure S3 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
77. Supplementary Table 1 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
78. Supplementary Tables 1-2 from EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
79. Supplementary Figure Legends 1-5 from Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
80. Supplementary Table 2 from Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer
81. Supplementary Table 3 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
82. Data from Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
83. Supplementary Table 1 from Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer
84. Figures S1-9 and Legends from EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
85. Supplementary Table 2 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
86. Supplementary Table S2 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
87. Supplementary Figure Legends 1-3 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
88. Supplementary Figure 1 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
89. Supplementary Figure 3 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
90. Supplementary Table 4 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
91. Supplementary Table 1 from Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer
92. Table 1 from Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
93. Supplementary Table 3 from Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer
94. Data from EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
95. Abstract P5-02-07: Cell-free DNA detection of GATA3 mutations in metastatic hormone receptor positive breast cancer: a retrospective, observational multi-institutional analysis
96. Abstract P6-10-10: Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan
97. ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression
98. A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas
99. Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
100. Pharmacodynamic Studies in Early Phase Drug Development
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.